A first report of radioembolization for hepatic metastases from ocular melanoma.
BACKGROUND
Ocular melanoma (OM) metastasizes to the liver and is rapidly fatal despite aggressive therapy. Yttrium-90 microspheres (radioembolization) delivered via the hepatic artery is an established and effective approach for primary and metastatic hepatic tumors, although (90)Y use in OM has not been reported previously.


METHODS
A retrospective review was performed for all patients with OM who received radioembolization at 5 centers.


RESULTS
11 patients received 12 treatments with a median activity of 1.55 GBq delivered per treatment. Toxicity was minimal, with PET/CT at 3 months posttreatment showing a response in all patients; 1 patient had a complete response.


CONCLUSIONS
Radioembolization can control hepatic metastases of OM with very few side effects.
Kennedy
Andrew S
AS
Wake Radiology Oncology, Cary, North Carolina 27518, USA. akennedy@wakerad.com
Nutting
Charles
C
Jakobs
Tobias
T
Cianni
Roberto
R
Notarianni
Ermanno
E
Ofer
Amos
A
Beny
Alex
A
Dezarn
William A
WA
D000328:Adult; D000368:Aged; D015901:Angiography, Digital Subtraction; D001918:Brachytherapy / Q000009:adverse effects; D004621:Embolization, Therapeutic / Q000009:adverse effects; D005060:Europe; D005134:Eye Neoplasms / Q000473:pathology*; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007270:Injections, Intra-Articular; D007557:Israel; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary; D008279:Magnetic Resonance Imaging; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary; D008863:Microspheres; D008875:Middle Aged; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014481:United States; D015021:Yttrium Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes